Multiparticulate Chitosan-Dispersed System for Drug Delivery
A multiparticulate chitosan-dispersed system (CDS), which is composed of the drug reservoir and the drug release-regulating layer, was developed for drug delivery. The drug release-regulating layer is a mixture of waterinsoluble polymer and chitosan powder. The drug is released from CDS pellets in all regions of the gastrointestinal tract (from the stomach to the colon). CDS pellets containing chitosan powder were designed to dissolve chitosan powder partly in the release-regulating layer in the stomach and release part of drug. After passing through the stomach, the drug is released from CDS pellets at a constant speed in the small intestine. In the large intestine, CDS pellets were designed to disintegrate the remaining chitosan powder at an accelerated speed and the remaining drug in CDS pellets is released. The drug release rate can be controlled with the thickness of the chitosan-dispersed water-insoluble layer. Furthermore, for colon-specific drug delivery, an additional outer enteric coating is necessary to prevent drug release from CDS pellets in the stomach, because the chitosan-dispersed water-insoluble layer dissolves gradually under acidic conditions. The resulting enteric-coated CDS (E-CDS) pellets were found to permit colon-specific drug delivery. In this study, the multiparticulate CDS was adopted not only for colon-specific drug delivery but also for sustained drug release.
55/Mg-St/95% ethanolϭ5/4/95) (84 g as a solid) were layered on the surface of CDS-7 h pellets (360 g). The operating conditions were the same as for the preparation of CDS pellets, except that the liquid flow rate was 4.3 g/min.
Morphological Examination The surface of pellets and chitosan powder were examined under a scanning electron microscope (SEM, JSM-T20, JEOL Ltd., Japan). Mean diameters of pellets were calculated based on the area of pellets (nϭ10). Areas of pellets were obtained by morphological observation under an optical microscope (Digital HD Microscope VH-7000, KEYENCE, Japan).
In Vitro Release Testing Release testing (300 mg as AAP) was carried out in accordance with the Japanese Pharmacopoeia (JP XIV) rotating basket method (100 rpm). Three fluids, i.e., JP 1st fluid simulating gastric juice (pH 1.2 aqueous solution), JP 2nd fluid simulating intestinal fluid (pH 6.8 phosphate buffer), and pH 4.0 acetate buffer, in which chitosan powder was easily dissolved, were used as dissolution media. Concentrations of AAP in the dissolution media were determined spectrophotometrically (detection wavelength, 247 nm).
In Vitro Degradation of CDS Pellets in Rat Cecal Contents Fresh rat cecal contents (18 g ) were suspended in the 2nd fluid (250 ml) and divided into two groups. One was heat-treated at 80°C for 30 min and the other was not heat-treated. CDS pellets were added to the two group liquids. Each liquid was stirred for 4 h at 37°C under aerobic conditions.
In Vivo Testing Male Wistar rats weighing 240-260 g were fasted for 24 h prior to oral administration of AAP solution (4 mg/ml, 10 mg/kg rat body weight as AAP) or pellets (10 mg/kg rat body weight as AAP) with 0.5 ml of water. Blood samples (0.25 ml) were collected from the jugular vein using heparinized syringes at designated time intervals. AAP plasma concentrations were determined by the modified HPLC method 16) with an internal standard of 2-acetaminophenol. A mixture of pH 3.0 phosphate buffer/acetonitrile/methanol (10/1/0.5 v/v) was used as the mobile phase at a flow rate of 1.0 ml/min. HPLC was performed on an ODS C 18 column (150 mmϫ6.0 mm) kept at 40°C with an ultraviolet detector (detection wavelength, 247 nm).
Time to peak concentration (T max ), maximum plasma concentration (C max ), area under the plasma concentration-time curve (AUC ), and mean residence time (MRT ) were calculated with the noncompartment method. To compare bioavailability between different preparations, Student's t-tests, were performed using the SAS statistical analysis software package (SAS Institute, Cary, NC, U.S.A.). A probability level of pϽ0.05 was considered statistically significant.
Results and Discussion
Fundamental Structure of CDS Pellets The basic structure of CDS pellets is schematically shown in Fig. 1 . The drug core containing the active ingredient was coated with chitosan-dispersed water-insoluble polymer. Water-insoluble polymers such as Eudragit RS are difficult to dissolve in acidic medium in which chitosan dissolves. To obtain the bi-functional release characteristics, i.e., time dependent and sitespecific, drug cores should be coated with chitosan-dispersed water-insoluble polymer. By adjusting the layer characteristics, the release site of drug in the gastrointestinal tract may be controlled. Especially for colon-specific drug delivery, an additional outer enteric coating is necessary to prevent the drug release from CDS pellets in the stomach, since the dispersed chitosan gradually dissolves under acidic conditions. CDS pellets with this outer enteric film (entericcoated CDS pellets, E-CDS pellets) could exhibit release characteristics for colon-specific drug delivery.
Morphological Examination Figure 2 shows scanning electron microphotographs of chitosan powder particles (A), seed core (B), drug core (C), E-drug (D), and representative CDS pellet (E) and E-CDS pellet (F). The diameters of these pellets were around 1.0 mm.
Sustained Drug Release Using CDS Pellets CDS pellets were prepared for sustained drug release and in vitro and in vivo evaluations were carried out.
(1) Dissolution Profiles of CDS Pellets: Figure 3A shows release profiles of AAP from CDS pellets (CDS-2 h, CDS-4 h and CDS-7 h) or SR pellets in artificial intestinal fluid (2nd fluid). Diameters [meanϮS.D. (nϭ10)] of drug core, CDS-2 h pellets, CDS-4 h pellets and CDS-7 h pellets were 1062Ϯ31 mm, 1128Ϯ48 mm, 1178Ϯ55 mm and 1338Ϯ27 mm, respectively. As a results, the thickness of the chitosandispersed layer of CDS-2 h pellet, CDS-4 h pellet and CDS-7 h pellet were about 33 mm, 58 mm, and 138 mm, respectively. The release rate of AAP decreased with the increasing thickness of the layer. These results indicate that the drug release rate could be controlled by the thickness of the chitosan-dispersed layer in the gastrointestinal tract. The release rate from CDS pellets in artificial gastric juice (1st fluid, Fig.  3B ) was more rapid than that in the 2nd fluid. To ascertain the effect of the dispersed chitosan powder in the release-regulating layer, SR pellets in which the release-regulating layer was composed of Eudragit RS alone were prepared. Drug release profiles of SR pellets were not affected by the pH difference of the dissolution medium (Fig. 3) . These results suggest that chitosan powder dispersed in the release-regulating layer dissolves in acidic conditions and the permeability of the drug to the layer increases in the 1st fluid. It is concluded that the dispersed chitosan powder in the release-regulating layer plays an important role in drug release from CDS pellets.
The gastrointestinal transit of pharmaceutical dosage forms was reported by Davis et al. 17) According to the literature, the average gastric emptying time and small intestinal transit time is 2 h and 3 h, respectively. Therefore release tests of CDS-7 h pellets were carried out in the 1st fluid for 2 h and immediately followed by the 2nd fluid for 3 h, i.e., under simulated gastrointestinal conditions of pH and transit times as shown in Fig. 4 . In spite of the drug release lag time from the preparations, the drug release rate increased for 1 h in the 1st fluid and the drug release rate was constant for 3 h in the 2nd fluid. After replacement of the medium with a pH 4.0 buffer solution, in which chitosan powder was easily dissolved, the release of drug markedly increased. It was recently reported that the pH in the colon is actually lower than that in the small intestine due to the acidification of colonic contents by products of bacterial fermentation. 18, 19) The decrease in pH on entry into the colon is due to the presence of short-chain fatty acids arising from the bacterial fermentation of polysaccharides. Furthermore, the pH in the colon was reduced in a group of untreated ulcerative colitis disease patients and the pH in the colon often drops to between 1 and 
5.
19) It is considered that dissolution testing using pH 4.0 buffer reflects the release profile of AAP from CDS pellets when dispersed chitosan powder was degraded. When using rat cecal contents as the dissolution medium, the release profile of AAP from CDS pellets was affected by the conditions of cecal content. Therefore, from the viewpoint of simplification of the evaluation, pH 4.0 buffer solution in which chitosan powder was the most easily dissolved was used in this study.
(2) Morphological Examinations of CDS Pellets Treated with Rat Cecal Contents: Chitosan is known to be degraded by enzymes 14) and to be dissolved in acidic medium. Therefore to ascertain its effect, fluid in which rat cecal contents was suspended in the 2nd fluid (chitosan is not dissolved in this fluid) was prepared. One was heat-treated at 80°C for 30 min and the other was not treated, because in general, enzymes are very sensitive to heat. The surfaces of each CDS pellet are shown in Fig. 5 . Figure 5A shows the surface of intact CDS pellets, and Fig. 5B and 5C show the surface of CDS pellets which were treated with rat cecal contents. It was found that the surface of CDS pellets (A) was degraded when the rat cecal contents were not heat-treated (C). On the other hand, the surface of the CDS pellets did not change in the suspension which was heat-treated for 30 min at 80°C (B). This means that chitosan powder in the release-regulating layer is degraded by contents that are sensitive to heat. It is therefore suggested that drug release from CDS pellets may increase when they are exposed to enzymes in the colon. Figure 6 shows the plasma concentration vs. time curve of AAP after oral administration of AAP solution (solution), CDS-2 h, and CDS-7 h pellets to rats. Pharmacokinetic parameters are presented in Table 1 . After oral administration of CDS pellets, decreased C max and prolonged T max and MRT were observed as compared with those after oral administration of solution. However, there were no statistically significant differences in the AUC between the three preparations. T max and MRT increased with the increasing coating level of the release-regulating layer of CDS pellets.
Based on results of in vitro tests (Fig. 3) , dispersed chitosan in CDS-2 h pellets was considered to dissolve in fair amounts in the stomach, and the drug might be released in the stomach and the small intestine. In the case of CDS-7 h pellets, it is considered that dispersed chitosan dissolves in part in the stomach, and the remaining chitosan is degraded in the colon, resulting in drug release in wide regions of the gastrointestinal tract, i.e., from the stomach to the colon.
Colon-Specific Drug Delivery Using E-CDS Pellets CDS-7 h pellets released small amounts of drug for 2 h in the 1st fluid, but not for more than 3 h in the 2nd fluid (Fig. 3) . For colon-specific drug delivery, E-CDS pellets were prepared by coating enteric polymer on CDS pellets and in vitro and in vivo evaluations were carried out.
(1) Dissolution Profile of E-CDS Pellets: Figure 7 shows release profiles of AAP from E-CDS pellets and E-Drug pellets under simulated gastrointestinal conditions of pH and transit times. E-Drug pellets were prepared by coating enteric polymer on drug cores without chitosan-dispersed layer. No drug release from E-CDS pellets was observed in the 1st fluid more than 2 h, and after replacement of the medium with the 2nd fluid, almost no drug was released in the subsequent 3 h. Thereafter the drug was markedly released from E-CDS pellets when the medium was replaced with a pH 4.0 buffer, in which chitosan powder in the release-regulating layer was easily dissolved. E-Drug pellets released the drug immediately after replacement of medium with the 2nd fluid.
(2) In Vivo Evaluation of E-CDS Pellets: Figure 8 shows plasma concentration vs. time curves of AAP after oral administration of E-CDS and E-Drug pellets in rats, and pharmacokinetic parameters are listed in Table 2 . Plasma levels of AAP were not detected within 4 h after oral administration of solution (Fig. 6 ) and E-Drug pellets. However, in the case of E-CDS pellets, AAP was detected in plasma for 4-24 h after oral administration. The T max and MRT after E-CDS pellet dosing were 9.3 h and 10.0 h, respectively, which were significantly longer than those after administration of solution, CDS pellets (Table 1 ) and E-Drug pellets. This result was in good agreement with the in vitro dissolution characteristics of E-CDS pellets (Fig. 7) . Therefore it is concluded that E-CDS pellets pass intact through the stomach and the small intestine, and when pellets reach the colon, chitosan in the release-regulating layer is dissolved under colonic conditions of pH or is degraded by enzymes, 14) resulting in colonspecific drug delivery.
Conclusions
In the present study, CDS was adopted for a multiparticulate system (CDS pellets). The drug release rate increased as chitosan powder dissolved in the stomach, but the drug release rate in the small intestine was constant and markedly increased in the colon. The drug release rate was controlled by the thickness of the chitosan-dispersed water-insoluble polymer. CDS pellets were found to be effective for longterm drug release in wide regions of the gastrointestinal tract. For colon-specific drug delivery, CDS pellets were further coated with an enteric polymer. The resultant enteric-coated CDS (E-CDS) pellets were found to be a useful drug delivery system for the colon. 
